What is claimed is:

1.   A conditionally lethal molecule comprising a chemical inducer binding domain and an apoptosis inducing factor, wherein said apoptosis inducing factor is an apoptosis signal transducing factor.

2.   A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is an adaptor molecule.

3.   A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is a protease.

4.   A conditionally lethal molecule according to claim 1, wherein said apoptosis inducing factor is a caspase.

5.   A nucleic acid molecule encoding the conditionally lethal molecule of any one of claims 1-4.

6.   A nucleic acid molecule according to claim 5, further comprising a sequence coding for tissue specific expression operatively linked to a sequence coding for a conditionally lethal molecule.

7.   A gene therapy vector comprising a nucleic acid sequence coding for the expression of a conditionally lethal molecule according to anyone of claims 1-4.

8.   A gene therapy vector according to claim 7, further comprising a sequence coding for a therapeutic gene.

9.   A gene therapy vector according to claim 7, further comprising a sequence coding for tissue specific expression operatively linked to a sequence coding for a conditionally lethal molecule.

10.   A transgenic animal expressing a conditionally lethal molecule according to any one of claims 1-4.

11.   A method of making a transgenic animal comprising the step of micro-injecting a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

12.   A method of treating a disease comprising the step of administering a vector that encodes a conditionally lethal molecule according to any one of claims 1-4.

13.   A method according to claim 12, wherein the disease is a hyperproliferative disease.

14.   A method according to claim 13, wherein the hyperproliferative disease is a benign disease.

15.   A method according to claim 14, wherein the disease is a malignant disease.

16.   A method according to claim 12, wherein the disease is atherosclerosis.

17.   A method of causing regression of a tumor comprising transfecting cells of said tumor with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

18.   A method according to claim 17 further comprising administering a CID.

19.   A method of causing a reduction in tumor size comprising transfecting cells of said tumor with a nucleic acid molecule encoding a conditionally lethal molecule
5   according to any one of claims 1-4.

20.   A method according to claim 19 further comprising administering a CID.

21.   A method of causing a reduction in PSA levels comprising transfecting cells of a tumor with a nucleic acid molecule encoding a conditionally lethal molecule
10   according to any one of claims 1-4.

22.   A method according to claim 21 further comprising administering a CID.

23.   A method of affecting the rate of cell proliferation caused by BPH comprising transfecting prostate cells with a nucleic acid molecule encoding a conditionally
15   lethal molecule according to any one of claims 1-4.

24.   A method according to claim 23 further comprising administering a CID.

25.   A method of inducing apoptosis in a cell comprising transfecting said
20   cell with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4.

26.   A method according to claim 26 further comprising administering a CID.

27. A method for determining the biological role of a cell type, comprising transfecting a cell of said cell type with a nucleic acid molecule encoding a conditionally lethal molecule according to any one of claims 1-4 and administering a CID.

65